Evidence map›Paper›PMID 41533581›Full record

ArticleNucleic acids research2026

Optimized CRISPR-Cas9 system for efficient engineering of ecDNA in cancer cells.

Yohei Sugimoto, Takeru Kachi, Yu Watanabe, Mei Kubokawa, Koichi Ogami, Masaki Kawamata, Seiko Yoshino, Hiroshi I Suzuki

Erratum issuedAbstract read
In one paragraph

Article in Nucleic acids research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Yohei SugimotoDivision of Molecular Oncology, Center for Neurological Diseases and Cancer, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan.ORCID 0009-0004-5845-5021
Takeru KachiDivision of Molecular Oncology, Center for Neurological Diseases and Cancer, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan.
Yu WatanabeDivision of Molecular Oncology, Center for Neurological Diseases and Cancer, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan.
Mei KubokawaDivision of Molecular Oncology, Center for Neurological Diseases and Cancer, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan.
Koichi OgamiDivision of Molecular Oncology, Center for Neurological Diseases and Cancer, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan.ORCID 0000-0001-9380-9666
Masaki KawamataDivision of Organogenesis and Regeneration, Medical Institute of Bioregulation, Kyushu University, Fukuoka 812-8582, Japan.
Seiko YoshinoDivision of Molecular Oncology, Center for Neurological Diseases and Cancer, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan.
Hiroshi I SuzukiDivision of Molecular Oncology, Center for Neurological Diseases and Cancer, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan.ORCID 0000-0003-4682-5086

Funding

Inamori Research Institute for ScienceJapan Agency for Medical Research and Development JP22ama221111Japan Agency for Medical Research and Development JP23ck0106791Japan Agency for Medical Research and Development JP23kk0305026Japan Agency for Medical Research and Development JP23tk0124003Japan Agency for Medical Research and Development JP24ck0106875Japan Agency for Medical Research and Development JP25ak0101291Japan Agency for Medical Research and Development JP25ck0106019Japan Agency for Medical Research and Development JP25kk0305028Japan Society for the Promotion of Science 19K24694Japan Society for the Promotion of Science JP22K06925Japan Society for the Promotion of Science JP24H00614Japan Society for the Promotion of Science JP25K10464JSPS 24KJ1238JST-SPRINGNagoya Universityoray Science Foundation 22-6304Takeda Science Foundation
6 · The paper itself

Abstract

Extrachromosomal DNA (ecDNA) amplification represents an emerging mechanism underlying oncogene amplification, tumor heterogeneity, and drug resistance in cancer. However, the biology of ecDNA remains poorly understood because tools to engineer ecDNAs and precisely monitor their dynamics are limited. In particular, genome engineering strategies have not been established for ecDNA, which exists in tens to hundreds of copies within a single cell. Here, we report a systematic validation of ecDNA editing using standard CRISPR-Cas9 system and optimized CRISPR-Cas9 system with safeguard single-guide RNAs (sgRNAs), in which the addition of cytosine extensions finely reduces excessive Cas9 activity. The conventional CRISPR-Cas9 system induced severe cytotoxicity and markedly reduced ecDNA copy number, together with frequent micronucleus formation. Knock-in efficiency was remarkably low, highlighting an intrinsic difficulty in editing ecDNA. In contrast, the safeguard sgRNA strategy not only alleviated cytotoxicity and ecDNA loss in a cytosine-length-dependent manner but also enabled efficient knock-in into multiple ecDNA per cell. Computational simulations suggested that the degree and temporal patterns of multiple DNA cleavage events shape cell death, micronucleus formation, and rapid expansion of knock-in ecDNA. Collectively, optimization of Cas9 activity using safeguard sgRNAs enables efficient and nondisruptive ecDNA engineering, providing a powerful tool to study ecDNA biology.

Indexed as

CRISPR-Cas SystemsExtrachromosomal DNAGene EditingNeoplasmsCell Line, TumorGene Knock-In TechniquesHumansRNA, Guide, CRISPR-Cas SystemsExtrachromosomal DNARNA, Guide, CRISPR-Cas Systems

Identifiers

PMID41533581
PMCPMC12802944

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.